CD47-SIRPα Checkpoint Disruption in Metastases Requires Tumor-Targeting Antibody for Molecular and Engineered Macrophage Therapies

CD47-SIRPα Checkpoint Disruption in Metastases Requires Tumor-Targeting Antibody for Molecular and Engineered Macrophage Therapies

The macrophage checkpoint interaction CD47-SIRPα is an emerging target for cancer therapy, but clinical trials of monoclonal anti-CD47 show efficacy only in liquid tumors when combined with tumor-opsonizing IgG. Here, in challenging metastatic solid tumors, CD47 deletion shows no effect on tumor gro...

Full description

Bibliographic Details
Main Authors: Andrechak, J.C (Author), Discher, D.E (Author), Dooling, L.J (Author), Hayes, B.H (Author), Irianto, J. (Author), Jin, X. (Author), Lee, J.Y (Author), Tobin, M.P (Author), Zhang, W. (Author)
Format: Article
Language:English
Published: MDPI 2022
Subjects:
B16F10
CD47
cell therapy
immunocompetent
immunotherapy
macrophage checkpoint
melanoma
metastasis
SIRPα
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items